

David Arroyo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9408398/publications.pdf>

Version: 2024-02-01

51
papers

1,880
citations

393982

19
h-index

264894

42
g-index

52
all docs

52
docs citations

52
times ranked

2934
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1388-1393.	2.2	670
2	COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1973-1983.	0.4	312
3	COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain. <i>Kidney International</i> , 2020, 98, 27-34.	2.6	259
4	Predictors of Subclinical Atheromatosis Progression over 2 Years in Patients with Different Stages of CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 287-296.	2.2	54
5	Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study. <i>BMC Nephrology</i> , 2014, 15, 168.	0.8	51
6	Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 467-474.	0.4	47
7	Present and Future in the Treatment of Diabetic Kidney Disease. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-13.	1.0	32
8	Bloodstream infections in patients with kidney disease: risk factors for poor outcome and mortality. <i>Journal of Hospital Infection</i> , 2013, 85, 196-205.	1.4	31
9	New perspectives on CKD-induced dyslipidemia. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 967-976.	1.5	31
10	An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 619-630.	1.5	29
11	Albumin Leakage in Online Hemodiafiltration, More Convective Transport, More Losses?. <i>Therapeutic Apheresis and Dialysis</i> , 2015, 19, 267-271.	0.4	28
12	Factors influencing pathological ankle-brachial index values along the chronic kidney disease spectrum: the NEFRONA study. <i>Nephrology Dialysis Transplantation</i> , 2016, 32, gfw039.	0.4	28
13	Intraindividual Interleukin-6 Variations on the Cardiovascular Prognosis of Patients with Chronic Renal Disease. <i>Renal Failure</i> , 2012, 34, 1002-1009.	0.8	25
14	Intraperitoneal Fluid Overestimates Hydration Status Assessment by Bioimpedance Spectroscopy. <i>Peritoneal Dialysis International</i> , 2015, 35, 85-89.	1.1	24
15	Factors predicting cardiovascular events in chronic kidney disease patients. Role of subclinical atheromatosis extent assessed by vascular ultrasound. <i>PLoS ONE</i> , 2017, 12, e0186665.	1.1	24
16	Humoral Response to Third Dose of SARS-CoV-2 Vaccines in the CKD Spectrum. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 872-876.	2.2	24
17	Metformin-Associated Acute Kidney Injury and Lactic Acidosis. <i>International Journal of Nephrology</i> , 2011, 2011, 1-5.	0.7	23
18	Utility of bioimpedance spectroscopy (BIS) in the management of refractory hypertension in patients with chronic kidney disease (CKD). <i>Nephrology Dialysis Transplantation</i> , 2012, 27, iv31-iv35.	0.4	21

#	ARTICLE	IF	CITATIONS
19	Estudio de intervenci3n aleatorizado para evaluar la prevalencia de enfermedad ateromatosa y renal ocultas y su impacto en la morbimortalidad: Proyecto ILERVAS. Nefrologia, 2016, 36, 389-396.	0.2	20
20	Skin Autofluorescence and Subclinical Atherosclerosis in Mild to Moderate Chronic Kidney Disease: A Case-Control Study. PLoS ONE, 2017, 12, e0170778.	1.1	15
21	Randomised intervention study to assess the prevalence of subclinical vascular disease and hidden kidney disease and its impact on morbidity and mortality: The ILERVAS project. Nefrologia, 2016, 36, 389-396.	0.2	13
22	Chronic kidney disease progression in patients with autosomal dominant polycystic kidney disease. Nefrologia, 2012, 32, 197-205.	0.2	13
23	Mineral metabolism factors predict accelerated progression of common carotid intima-media thickness in chronic kidney disease: the NEFRONA study. Nephrology Dialysis Transplantation, 2016, 32, gfw306.	0.4	12
24	Adjuvant Ciprofloxacin for Persistent BK Polyomavirus Infection in Kidney Transplant Recipients. Journal of Transplantation, 2014, 2014, 1-8.	0.3	11
25	Toxinas unidas a proteÃnas: valor aÃadido en su eliminaci3n con altos volÃmenes convectivos. Nefrologia, 2016, 36, 637-642.	0.2	8
26	Recovery of dialysis patients with COVID-19: health outcomes 3 months after diagnosis in ERACODA. Nephrology Dialysis Transplantation, 2022, 37, 1140-1151.	0.4	7
27	High-Sensitivity Troponin T Levels in Kidney Transplant Recipients. Transplantation Proceedings, 2012, 44, 2545-2547.	0.3	6
28	Protein-bound toxins: Added value in their removal with high convective volumes. Nefrologia, 2016, 36, 637-642.	0.2	6
29	Infective endocarditis on a percutaneous prosthetic aortic valve with associated glomerulopathy due to Granulicatella adjacens. Brazilian Journal of Infectious Diseases, 2012, 16, 601-602.	0.3	5
30	Monitoring of Circulating Antibodies in a Renal Transplantation Population: Preliminary Results. Transplantation Proceedings, 2012, 44, 2548-2550.	0.3	5
31	MÃs allÃ de los parÃmetros lipÃdicos tradicionales en la enfermedad renal crÃnica. Nefrologia, 2018, 38, 109-113.	0.2	5
32	Hypercalcemia as a side effect of potassium binding agents. Nefrologia, 2012, 32, 655-8.	0.2	5
33	Beyond the traditional lipid parameters in chronic kidney disease. Nefrologia, 2018, 38, 109-113.	0.2	4
34	Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease. BMC Nephrology, 2021, 22, 110.	0.8	4
35	Pancreatitis y hepatitis agudas por hemÃlisis secundaria a trombectomÃa farmacomecÃnica percutÃnea de acceso vascular protÃsico para hemodiÃlisis. Nefrologia, 2019, 39, 104-105.	0.2	3
36	High doses of irbesartan offer long-term kidney protection in cases of established diabetic nephropathy. Nefrologia, 2012, 32, 187-96.	0.2	3

#	ARTICLE	IF	CITATIONS
37	Proteinuria-Lowering Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Chronic Kidney Disease Patients: A Real-World Multicentric Study. <i>Metabolites</i> , 2021, 11, 760.	1.3	3
38	A Spanish multicentric study to evaluate the clinical activity of nephrology fellows during in-hospital on-call shifts. <i>CKJ: Clinical Kidney Journal</i> , 2013, 6, 556-560.	1.4	2
39	Renal long-term outcome of critically ill COVID-19 patients with acute kidney failure and continuous renal replacement therapy. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2449-2450.	1.4	2
40	The effect of replacing aluminium hydroxide with calcium acetate/magnesium carbonate on serum phosphorus control in haemodialysis patients. <i>Nefrologia</i> , 2014, 34, 199-204.	0.2	2
41	Acute kidney injury secondary to very severe hypercalcaemic crisis caused by primary hyperparathyroidism. <i>Nefrologia</i> , 2015, 35, 224-226.	0.2	1
42	Impact of the Limitations in Fluid Overload Assessment by Bioimpedance Spectroscopy. <i>Peritoneal Dialysis International</i> , 2015, 35, 604-604.	1.1	1
43	Impact of preoperative exercise in not initially candidates to native arteriovenous fistulas. <i>Journal of Vascular Access</i> , 2021, , 112972982110455.	0.5	1
44	FP353RISK FACTORS FOR PROGRESSION OF COMMON INTIMA α THICKNESS IN INDIVIDUALS WITH CHRONIC KIDNEY DISEASE: THE NEFRONA STUDY. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii186-iii186.	0.4	0
45	FP359SUBCLINICAL PERIPHERAL ARTERY DISEASE PREDICTS CARDIOVASCULAR EVENTS IN CHRONIC RENAL IMPAIRMENT: THE NEFRONA PROJECT. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii188-iii189.	0.4	0
46	FP373FACTORS PREDICTING SUBCLINICAL ATHEROMATOSIS PROGRESSION IN CHRONIC KIDNEY DISEASE. THE NEFRONA STUDY. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii193-iii193.	0.4	0
47	SP357PROGRESSION OF PERIPHERAL ARTERY DISEASE IN CHRONIC RENAL IMPAIRMENT: THE NEFRONA PROJECT. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii497-iii497.	0.4	0
48	Subclinical atheromatosis progression and associated risk factors in chronic kidney disease. The nefrona study. <i>Atherosclerosis</i> , 2015, 241, e14-e15.	0.4	0
49	MP267THE NUMBER OF ARTERIAL TERRITORIES WITH ATHEROMA PLAQUE PREDICTS THE TIME FREE FROM CARDIOVASCULAR EVENTS IN CHRONIC KIDNEY DISEASE. ANALYSIS OF THE NEFRONA STUDY AFTER 36 MONTHS OF FOLLOW-UP. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i429-i429.	0.4	0
50	Acute haemolytic pancreatitis and hepatitis secondary to percutaneous pharmacomechanical thrombectomy of prosthetic vascular access for haemodialysis. <i>Nefrologia</i> , 2019, 39, 104-105.	0.2	0
51	Lupus nephritis and thin glomerular basement membrane coexistence: case report and review of the literature. <i>International Urology and Nephrology</i> , 2021, , 1.	0.6	0